Orris

New updates on hyponatraemia

Reading File
Reading File
Finding Sources
Searching PubMed

"hyponatremia"[MeSH Terms] AND "guideline"[pt]

Searching PubMed

hyponatremia management

Searching the Web

new updates hyponatremia guidelines 2025 2026

Reading Article

PMID: 39556338

Reading Article

PMID: 37379081

Reading Article

PMID: 39362395

Reading Web Page

https://www.medscape.com/viewarticle/debate-fast-or-slow-cor…

New Updates on Hyponatraemia

The biggest story in hyponatraemia over the past 1-2 years is a genuine controversy over how fast severe hyponatraemia should be corrected — new evidence is pushing back against the conservative correction limits that have been standard since 2014.

1. Rapid vs. slow correction: guidelines under challenge

Current international guidelines (ESE/ERA-EDTA 2014, widely adopted since) recommend limiting correction of severe hyponatraemia to roughly 8-10 mmol/L per 24 hours (lower, ~8 mmol/L/d, in high-risk patients) to avoid osmotic demyelination syndrome (ODS). Several large analyses now question whether this is too cautious:
  • [Systematic Review/Meta-Analysis, 2025] Ayus, Moritz et al., JAMA Internal Medicine - pooled 16 cohort studies (~11,800 patients with severe hyponatraemia). Rapid correction (≥8-10 mmol/L/24h) was associated with fewer in-hospital deaths (32 fewer per 1000 vs. slow correction; 221 fewer per 1000 vs. very slow correction) and fewer 30-day deaths, plus shorter hospital stay, with no significant increase in ODS risk [PMID: 39556338].
  • [Systematic Review/Meta-Analysis, 2026] Matrisch et al., Emergency Medicine Journal - a newer meta-analysis again found a consistent mortality reduction with rapid correction across the 8, 10, and 12 mmol/L/day thresholds. ODS remained rare overall but was somewhat more frequent with rapid correction. The authors concluded current guideline limits "may be too low" but stressed a properly powered RCT is needed before guidelines change.
  • Counterpoint - [Review, 2024] Sterns, Rondon-Berrios, Adrogué et al., CJASN, "Treatment Guidelines for Hyponatremia: Stay the Course" - a rebuttal from a group representing 20 centers across 9 countries, arguing the retrospective data have confounding (sicker patients may correct more slowly for reasons unrelated to treatment) and that clinicians should keep following the cautious limits until better (ideally randomized) evidence exists [PMID: 37379081].
  • This debate played out live at the NKF 2026 Spring Clinical Meetings, where Rondon-Berrios defended the existing 8 mmol/L/d limit for high-risk chronic hyponatraemia (baseline Na ≤105, alcohol use disorder, malnutrition, advanced liver disease, hypokalaemia/hypophosphataemia) while noting it was never meant for acute hyponatraemia or patients with Na ≥120. Opponents pointed out that in real practice, "slow correction" often fails anyway (one Canadian study found 69% of patients with Na <110 ended up correcting fast despite best efforts), raising medicolegal concerns about penalizing clinicians for something hard to control.
Bottom line for practice right now: guidelines have not formally changed. The prevailing recommendation is still to limit correction to about 8 mmol/L/24h in high-risk patients (max ~10-12 mmol/L/24h in average-risk patients), with careful monitoring. But expect this ceiling to be revisited if a prospective RCT confirms the observational mortality signal.

2. Urea re-emerging as a treatment for SIADH

[Systematic Review/Meta-Analysis, 2025] Chander et al., American Journal of Kidney Diseases - pooled observational data show oral/nasogastric urea raises serum sodium effectively in SIADH (mean rise ~9 mEq/L overall, up to ~18 mEq/L in severe cases), with efficacy comparable to fluid restriction and vaptans and only minor side effects (mainly poor palatability). No RCTs exist yet, but this supports urea as a practical, low-cost option, especially in resource-limited settings or when vaptans/fluid restriction are contraindicated or poorly tolerated [PMID: 39362395].

3. Regional consensus statements

  • Austrian Society for Nephrology 2024 consensus recommendations on diagnosis and treatment.
  • Spanish Society of Endocrinology and Nutrition (Acqua Group), 2023 consensus, with specific guidance on hypertonic saline and tolvaptan use.
  • A 2025 Swiss review (Revue Médicale Suisse) reiterating diagnostic/management algorithms for general practice.
These largely align with the 2014 European guideline framework but refine practical algorithms (volume status assessment, urine osmolality/sodium-based classification, staged correction).

4. Other notable recent findings

  • Hyponatraemia after subarachnoid haemorrhage remains common and is associated with worse outcomes (2025 systematic review/meta-analysis).
  • A large administrative-data study (~1.8 million admissions) refined prevalence estimates for hyponatraemia/hypernatraemia when corrected for co-existing solutes (e.g., glucose), suggesting true prevalence differs from uncorrected lab values.
  • Osmotic demyelination remains a rare but recognized complication of overly rapid correction, particularly in patients with hypokalaemia, malnutrition, or liver disease - this risk-stratification remains unchanged even amid the correction-rate debate.
  • Pediatric-specific updates (2024, Current Opinion in Pediatrics) emphasize avoiding hypotonic maintenance fluids in acutely ill children as a preventive strategy, consistent with prior guidance.

Practical takeaway

The framework taught in standard texts (classify by volume status, use urine osmolality/sodium, treat SIADH with fluid restriction/urea/vaptans, correct severe symptomatic hyponatraemia with hypertonic saline while monitoring closely) still stands - see for example Brenner and Rector's The Kidney and the National Kidney Foundation Primer on Kidney Diseases for the core algorithm. What's new is a live, unresolved debate about whether correction limits are too conservative, driven by large meta-analyses (JAMA IM 2025, Emerg Med J 2026) suggesting a mortality benefit from faster correction, met with strong pushback from guideline authors urging caution until randomized trial data exist. Also emerging: urea gaining fresh meta-analytic support as an effective SIADH treatment option.
If you want, I can go deeper into any one of these — the correction-rate controversy, SIADH treatment options, or a specific population (pediatric, elderly, liver disease).
This is a shared conversation. Sign in to Orris to start your own chat.